24. Sep 2026
Description
(AWP Alliance News) - Xlife Sciences AG posted a net loss of CHF 170.5 million for H1 2026, widening from CHF 5.8 million a year earlier, while basic earnings per share fell to CHF -29.08 from CHF -0.53. Revenue rose 34.4% to CHF 476,234, and gross profit more than doubled to CHF 394,269. Total assets fell to CHF 346.75 million at June 30 from CHF 536.3 million a year earlier, while equity dropped to CHF 206.32 million from CHF 391.9 million. The group said the remeasurement of its VERAXA stake after the NASDAQ listing resulted in a fair value loss of CHF 164.6 million, and noted founders extended existing convertible loans until mid-2029. VERAXA began trading on Nasdaq on June 11 under ticker VRXA, and management said H2 priorities include supporting VERAXA's operational progress and industry partnerships while advancing portfolio projects and partnering talks at saniva following two clinical studies of its NeuroMex screening device.
https://docs.publicnow.com/14A4676E16348A7E0BFF50CFA09E62B8853FD47A
Disclaimer: This news brief was created using generative artificial intelligence. Xlife Sciences AG published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.
